---
title: "Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Specific populations questions"
description: "Specific populations questions on Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: How does Kisqali safety compare in older patients with metastatic breast cancer? Can men with metastatic breast cancer take Kisqali? What is the Kisqali dose for liver (hepatic) impairment? 3 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Specific populations questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)

Specific populations questions that apply to every indication of Kisqali are on [Kisqali (ribociclib), all indications: Specific populations](https://www.evicenter.com/medical-information/kisqali/specific-populations).

## Specific populations

<a id="kisqali-older-patients-safety"></a>

### How does Kisqali safety compare in older patients with metastatic breast cancer?

Applies to: Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7

> “Of 334 patients with advanced or metastatic breast cancer who received KISQALI in MONALEESA-2, 150 patients (45%) 
> were ≥ 65 years of age and 35 patients (11%) were ≥ 75 years of age. Of 484 patients with advanced or metastatic breast 
> cancer who received KISQALI in MONALEESA-3, 226 patients (47%) were ≥ 65 years of age and 65 patients (14%) were 
> ≥ 75 years of age. Of 248 patients with advanced or metastatic breast cancer who received KISQALI in MONALEESA-7, 
> no patients were ≥ 65 years of age. No overall differences in safety or effectiveness of KISQALI were observed between 
> older and younger adults with advanced or metastatic breast cancer.”

Source: [KISQALI: Prescribing information, page 19, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=19)

> “Discontinuations due to AEs with KISQALI + ET<sup>1</sup>
>
> 15% in patients <65 years old
>
> 20% in patients 65 to <75 years old
>
> 41% in patients ≥75 years old”

Source: [KISQALI: Data Across Age Groups | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/data-across-age-groups#:~:text=Discontinuations%20due%20to%20AEs%20with,in%20patients%20%E2%89%A575%20years%20old)

> “The ≥75 years age group has a small sample size, and data should be interpreted with caution.”

Source: [KISQALI: Data Across Age Groups | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/efficacy/data-across-age-groups#:~:text=%2895%25%20CI%3A%2037.7%2D63.9%29.-,The%20%E2%89%A575%20years%20age%20group%20has%20a%20small%20sample%20size%2C,should%20be%20interpreted%20with%20caution.)

Note: The discontinuation rates by age are from an exploratory, pooled, post hoc analysis of first-line patients in MONALEESA-2, MONALEESA-3, and MONALEESA-7 on the data across age groups page of the Kisqali HCP site.

<a id="kisqali-men"></a>

### Can men with metastatic breast cancer take Kisqali?

Applies to: Men with HR-positive, HER2-negative advanced or metastatic breast cancer

> “KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in 
> combination with: 
> • 
> an aromatase inhibitor as initial endocrine-based therapy; or  
> • 
> fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.”

Source: [KISQALI: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=3)

> “Pre/perimenopausal women, or men, treated with the combination KISQALI plus an aromatase inhibitor or fulvestrant, 
> should be treated with a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice 
> standards.”

Source: [KISQALI: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=3)

> “COMPLEEMENT-1 (NCT 02941926) was an open-label, multicenter clinical study of ribociclib in combination with 
> letrozole and goserelin or leuprolide for the treatment of adults with HR-positive, HER2-negative, advanced breast cancer 
> who received no prior hormonal therapy for advanced disease.  
> The study included 39 male patients who received KISQALI 600 mg orally once daily for 21 consecutive days followed by 
> 7 days off; and letrozole 2.5 mg orally once daily for 28 days; and goserelin 3.6 mg as injectable subcutaneous implant or 
> leuprolide 7.5 mg as intramuscular injection administered on Day 1 of each 28-day cycle. Patients were treated until disease 
> progression or unacceptable toxicity occurred.”

Source: [KISQALI: Prescribing information, page 30, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=30)

> “Other adverse reactions occurring in men treated with KISQALI plus letrozole and goserelin or leuprolide were similar to 
> those occurring in women treated with KISQALI plus endocrine therapy.”

Source: [KISQALI: Prescribing information, page 16, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=16)

Note: COMPLEEMENT-1 was a single-arm study; the Prescribing Information reports its overall response rate and duration of response in a table.

<a id="kisqali-liver-impairment-dose"></a>

### What is the Kisqali dose for liver (hepatic) impairment?

> “No dose adjustment is necessary in patients with breast cancer who have mild hepatic impairment (Child-Pugh class A) [see 
> Clinical Pharmacology (12.3)]. A reduced starting dose of 400 mg is recommended in patients with advanced or metastatic 
> breast cancer who have moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) [see Dosage 
> and Administration (2.2)].”

Source: [KISQALI: Prescribing information, page 19, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=19)

> “The recommended starting dose is 400 mg once daily for patients with moderate or severe (Child-Pugh class B or C) hepatic impairment”

Source: [KISQALI: Dosing | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dosing#:~:text=The%20recommended%20starting%20dose%20is,B%20or%20C%29%20hepatic%20impairment)

## Related pages
- [Medical information: Kisqali (ribociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/guidelines)
